Functional (Non Ulcer) Dyspepsia – Pipeline Review, H2 2018 Featuring Daewoong Pharmaceutical, RaQualia Pharma & Zeria Pharmaceutical – ResearchAndMarkets.com

DUBLIN–(BUSINESS WIRE)–The “Functional
(Non Ulcer) Dyspepsia – Pipeline Review, H2 2018”
drug
pipelines has been added to ResearchAndMarkets.com’s
offering.

Functional (Non Ulcer) Dyspepsia – Pipeline Review, H2 2018, provides
comprehensive information on the therapeutics under development for
Functional (Non Ulcer) Dyspepsia (Gastrointestinal), complete with
analysis by stage of development, drug target, mechanism of action
(MoA), route of administration (RoA) and molecule type. The guide covers
the descriptive pharmacological action of the therapeutics, its complete
research and development history and latest news and press releases.

The Functional (Non Ulcer) Dyspepsia (Gastrointestinal) pipeline guide
also reviews key players involved in therapeutic development for
Functional (Non Ulcer) Dyspepsia and features dormant and discontinued
projects. The guide covers therapeutics under Development by Companies
/Universities /Institutes, the molecules developed by Companies in Phase
III, Phase II, Phase I and Preclinical stages are 2, 1, 2 and 1
respectively. Similarly, the Universities portfolio in Discovery stages
comprises 1 molecules, respectively.

Functional (Non Ulcer) Dyspepsia (Gastrointestinal) pipeline guide helps
in identifying and tracking emerging players in the market and their
portfolios, enhances decision making capabilities and helps to create
effective counter strategies to gain competitive advantage.

Key Topics Covered:

  1. Introduction
  2. Report Coverage
  3. Functional (Non Ulcer) Dyspepsia – Overview
  4. Functional (Non Ulcer) Dyspepsia – Therapeutics Development
  5. Pipeline Overview
  6. Pipeline by Companies
  7. Pipeline by Universities/Institutes
  8. Products under Development by Companies
  9. Products under Development by Universities/Institutes
  10. Functional (Non Ulcer) Dyspepsia – Therapeutics Assessment
  11. Assessment by Target
  12. Assessment by Mechanism of Action
  13. Assessment by Route of Administration
  14. Assessment by Molecule Type
  15. Functional (Non Ulcer) Dyspepsia – Companies Involved in Therapeutics
    Development
  • Daewoong Pharmaceutical Co Ltd
  • RaQualia Pharma Inc
  • Zeria Pharmaceutical Co Ltd

For more information about this drug pipelines report visit https://www.researchandmarkets.com/research/z68fsr/functional_non?w=4.

Contacts

ResearchAndMarkets.com
Laura Wood, Senior Manager
press@researchandmarkets.com
For
E.S.T. Office Hours Call 1-917-300-0470
For U.S./CAN Toll Free Call
1-800-526-8630
For GMT Office Hours Call +353-1-416-8900
Related
Topics: Gastrointestinal
Drugs